how does semaglutide reduce cardiovascular risk GLP-1 Agonists in Diseases: Mechanisms, Clinical Evidence, and Emerging Therapies Semaglutide cardiovascular outcomes align more

Description

This article explores current clinical evidence, provider decision-making frameworks, and how genetic insights may inform a personalized conversation with your healthcare

The nonprofit drug pricing watchdog Institute for Clinical and Economic Review on Wednesday released a new report outlining potential federal policy solutions to increase access to blockbuster obesity drugs known as GLP-1s.

The success of these agents in preclinical models and clinical trials suggests a promising future for multiagonists in the treatment of metabolic diseases, with the most recent glucose-dependent insulinotropic peptide receptor:glucagon-like peptide 1 receptor:glucagon receptor (GIPR:GLP-1R:GCGR) triagonists rivaling the efficacy of bariatric surgery

In the analysis of the efficacy of oral semaglutide at weeks 26 and 52 in Asian and non-Asian patients, in Asian patients, the hypoglycemic efficacy of oral semaglutide at 3-, 7-, and 14-mg doses at week 52 was significantly lower than that at week 26